Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis

Psoriasis is a chronic, inflammatory skin disease often requiring long-term therapy. To evaluate the long-term safety and efficacy of risankizumab in patients with psoriasis. Methods: LIMMitless is an ongoing phase 3, open-label extension study evaluating the long-term safety and efficacy of continu...

ver descrição completa

Detalhes bibliográficos
Autores: Papp, Kim A.|||0000-0001-9557-3642, Blauvelt, Andrew|||0000-0002-2633-985X, Puig Sanz, Lluís|||0000-0001-6083-0952, Ohtsuki, M., Beissert, Stefan, Gooderham, Melinda|||0000-0001-8926-0113, Amin, A.Z., Liu, Jianjun|||0000-0002-3255-3019, Wu, T., Azam, T., Stakias, V., Espaillat, R., Sinvhal, R., Soliman, Ahmed M., Pang, Y., Chen, M.M., Lebwohl, M. G.
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:296646
Acesso em linha:https://ddd.uab.cat/record/296646
https://dx.doi.org/urn:doi:10.1016/j.jaad.2023.07.1024
Access Level:acceso abierto
Palavra-chave:Interleukin 23
Plaque psoriasis
Psoriasis
Risankizumab
Descrição
Resumo:Psoriasis is a chronic, inflammatory skin disease often requiring long-term therapy. To evaluate the long-term safety and efficacy of risankizumab in patients with psoriasis. Methods: LIMMitless is an ongoing phase 3, open-label extension study evaluating the long-term safety and efficacy of continuous risankizumab 150 mg every 12 weeks for adults with moderate-to-severe plaque psoriasis following multiple phase 2/3 base studies. This interim analysis assessed safety (ie, monitored treatment-emergent adverse events [TEAEs]) through 304 weeks. Efficacy assessments included determining the proportion of patients who achieved ≥90% or 100% improvement in Psoriasis Area and Severity Index (PASI 90/100), static Physician's Global Assessment of clear/almost clear (sPGA 0/1), and Dermatology Life Quality Index of no effect on patient's life (DLQI 0/1) through 256 weeks. Among 897 patients randomized to risankizumab in the base studies, 706 were still ongoing at data cutoff. Rates of TEAEs, TEAEs leading to discontinuation, and TEAEs of safety interest were low. At week 256, 85.1%/52.3% of patients achieved PASI 90/100, respectively, 85.8% achieved sPGA 0/1, and 76.4% achieved DLQI 0/1. Limitations: Open-label study with no placebo or active-comparator group. Long-term continuous risankizumab treatment for up to 5 years was well tolerated and demonstrated high and durable efficacy.

Registos relacionados